Background: Chronic inflammatory demyelinating polyradiculoneuropathy is a rare acquired immune-mediated progressive or relapsing disorder causing peripheral neuropathic disease of duration more ...

Patients with CIDP with a high level of functional impairment as determined ... and the patient became a wheelchair user by June 2011. Treatment with rituximab at a weekly dose of 750 mg/m 2 /week for ...

He was kept under high-dose steroids and ciclosporin. He started treatment with rituximab (two administrations of 1 g 2 weeks apart, repeating after 6 months). The steroids dose was gradually reduced ...

The patient slowly improved since beginning rituximab and is now able to stand for short ... The patient was diagnosed with CIDP and started treatment with IVIG and methylprednisolone. However, the ...

Introduction While chronic inflammatory demyelinating polyneuropathy (CIDP) is the most common immune ... followed by corticosteroids (13 [28.3%]). Other treatment modalities (plasma exchange [3], ...

hsc.usc.edu Background: Rituximab, a chimeric monoclonal anti-CD20 antibody, has recently been used for the treatment of refractory antibody mediated autoimmune diseases such as immune mediated ...

Targeting malignant cells with rituximab is being used increasingly as local chemotherapy, but information on this treatment is scant. We aimed to describe current therapeutic approaches, as well as ...

Of these, no patient reported a treatment change. In patients with CIDP, the minimal clinically important difference ... ciclosporin, cyclophosphamide, rituximab, and mycophenolate mofetil, which ...

Intravenous cyclophosphamide (500 mg) with mesna followed by a single infusion of 1 g rituximab preceded by 100 mg of methylprednisolone intravenously was given. An absolute CD19 count 1 month after ...

A 3-year follow-up of patients with refractory/relapsed indolent non-Hodgkin (NHL) treated with a combination of magrolimab and rituximab showed no new treatment-emergent adverse events ...

Background: Rituximab (RTX) is a monoclonal antibody that has been increasingly used in the treatment of myasthenia gravis (MG). In most studies, the therapeutic protocol of RTX has been similar to ...